America of a famous hospital Scientists by Cancer A cell-killing drug has been developed that destroys solid tumors through ‘targeted chemotherapy’.
The pill contains a protein, for example, that acts like a ‘blizzard that can shut down an airline’s main hub and thus stop the flow of only planes carrying cancer cells.’
The protein was developed by a research team at City of Hope Hospital, one of the largest cancer research and treatment organizations in the United States.
A molecule called AOH1996 works by targeting the cancer variant of PCNA, a protein important for DNA replication and tumor growth.
Developed over the past two decades, this drug has proven effective in clinical research for the treatment of breast, prostate, brain, ovarian, cervical, skin and lung cancers.
In this study, published in the medical journal ‘Cell Chemical Biology’, this protein was tested on more than 70 cancer cell lines.
This section contains related reference points (Related Nodes field).
The results showed that the AOH1996 molecule selectively killed cancer cells by disrupting the normal reproductive cycle of the cell. The next step is to advance these findings through clinical trials in humans.
Dr Linda Malkas, PhD, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope and MT&BA Professor of Molecular Oncology, Ahmadineja said: ‘PCNA is like a large airline terminal hub with a More air gates are included. The data showed that PCNA is uniquely mutated in cancer cells and this fact helped us develop a drug that would target only the mutated form of PCNA in cancer cells. is.’
He added: ‘Our cancer-killing drug is like a blizzard that shuts down a major airline hub only to stop all flights carrying cancer cells.’
According to him: ‘The results have been promising. AOH1996 can inhibit tumor growth as a monotherapy without inducing toxicity in cell and animal models. The investigational chemotherapy is currently in a phase one human clinical trial at City of Hope.’
The study’s lead author, Long Guo, associate research professor in the Department of Molecular Diagnostics at Beckman Research Institute in the City of Hope, added: ‘No drug has ever targeted PCNA therapeutically. was made because it was considered ‘untreatable’ but clearly City of Hope was able to develop an investigational drug to target a challenging protein.’
According to him: ‘We discovered that PCNA is one of the possible causes of increased nucleic acid replication errors in cancer cells. Now that we know the specific part of the problem and can prevent it, we will go deeper to understand the process to develop more personalized and targeted cancer drugs.’
#Breakthrough #cancer #treatment #tumorkilling #drug #discovered
How does the targeted approach of AOH1996 improve patient outcomes in cancer therapy?
**Interview with Dr. Linda Malkas on the Development of AOH1996: A New Breakthrough in Cancer Treatment**
**Editor:** Thank you for joining us today, Dr. Malkas. Your team’s recent development of the drug AOH1996 has received significant attention. Can you explain what makes this drug different from traditional chemotherapy?
**Dr. Malkas:** Thank you for having me. What sets AOH1996 apart is its targeted approach to chemotherapy. Instead of attacking all rapidly dividing cells indiscriminately, AOH1996 specifically targets the cancer variant of the PCNA protein, which is crucial for DNA replication and tumor growth. This method minimizes damage to healthy cells, resulting in fewer side effects for patients.
**Editor:** That’s fascinating! You mentioned in your research that AOH1996 works like “a blizzard” disrupting the flow of cancer cells. Can you elaborate on that analogy?
**Dr. Malkas:** Certainly! Think of PCNA as a major airline hub. In a busy airport, the flow of planes represents the replication and growth of cells. When AOH1996 enters the system, it acts like a snowstorm that effectively halts operations at that hub. This disruption directly impacts the cancer cells, preventing them from multiplying and spreading, while sparing normal cells that aren’t dependent on this mutated hub.
**Editor:** Your study showed promise across various cancer types. Could you share which cancers AOH1996 has been proven effective against?
**Dr. Malkas:** Yes! In our clinical research, we’ve tested AOH1996 against breast, prostate, brain, ovarian, cervical, skin, and lung cancers. The drug has shown strong efficacy across these types, which is encouraging as it suggests a broad potential use in cancer therapy.
**Editor:** That’s impressive. What are the next steps for AOH1996 now that you’ve shown effectiveness in preclinical trials?
**Dr. Malkas:** The next step is to advance to human clinical trials. We’re dedicated to rigorously testing AOH1996 to ensure its safety and efficacy for patients. This transition will help us understand the drug’s effects in a real-world clinical setting and pave the way for regulatory approval.
**Editor:** Thank you, Dr. Malkas. This innovative approach to cancer treatment holds great promise, and we look forward to seeing how it progresses in future trials.
**Dr. Malkas:** Thank you for the opportunity to share our work. We are hopeful that AOH1996 can make a significant difference in the lives of cancer patients.
